Checkout

pharma-and-healthcare.webp

Antibacterial (Drug) Resistance Market Size, By Product Type (Telavancin (Vibativ), Ceftaroline Fosamil (Teflaro/ Zinforo), Fidaxomicin (Dificid / Dificlir), Ceftobiprole Medocaril (Zevtera/ Zeftera/ Mabelio), Dalbavancin (Dalvance/ Xydalba), Tedizolid Phosphate (Sivextro), Oritavancin (Orbactiv/ Nuvocid), Ceftolozane-Tazobactam (Zerbaxa), Ceftazidime-Avibactam (Avycaz/ Zavicefta), PHASE III DRUGS), By Application (Complicated Urinary Tract Infection (CUTI), Complicated Intra-Abdominal Infections (CIAI), Blood Stream Infections (BSI), Clostridium Difficile Infections (CDI), Acute Bacterial Skin And Skin Structure Infections (ABSSSI), Hospital Acquired Bacterial Pneumonia/Ventilator (HABP/VABP), Community Acquired Bacterial Pneumonia (CABP)), By Key Players (Melinta Therapeutics, Allergan, Merck, Abbott Laboratories, Pfizer, GSK, PENDOPHARM, Absynth Biologics, Achaogen, Acino Holdings, Av

Report ID - RV192213 | Publish Date - Dec 2023 | Pages - 147 | Price - $3260
Billing Information
Choose Licence Type
$3260
$4760
$6260
Payment Method

We Accept

payment-logo